Drug Discovery: From Lottery to Certainty - The Rise of AI
Ari Massoudi
I do stuff enabling Mankind to live longer, stronger and smarter ?????????=>??
The Serendipitous Discovery of Benzodiazepines: A Tale of Chemistry and Chance
Imagine a world where anxiety and insomnia were untreatable, where the only recourse was to suffer in silence. This was the reality until the mid-20th century, when a series of fortunate events led to the discovery of benzodiazepines, a class of drugs that revolutionized psychiatric treatment. Our story begins with Leo Sternbach, a brilliant chemist whose journey from war-torn Europe to the laboratories of Hoffmann-La Roche would forever change the landscape of mental health.
A Refugee Lands in New Jersey
Leo Sternbach was born in 1908 in Austria-Hungary (now Croatia), the son of a pharmacist. From a young age, he was captivated by chemistry, disassembling artillery shells to create his own fireworks—a dangerous hobby that fortunately never led to disaster. His family later moved to Krakow, Poland, where Leo earned his PhD in organic chemistry from the University of Krakow in 1931.
As anti-Semitism rose in Europe, Sternbach's Jewish heritage made his career choices critical. He worked briefly with future Nobel laureate Leopold Ruzicka in Zurich but felt his advancement was hindered by his background. In 1940, he joined Hoffmann-La Roche in Basel, Switzerland, a company that actively protected its Jewish employees. A year later, he was transferred to Nutley, New Jersey, where he would make his groundbreaking discoveries.
The Quest for a New Tranquilizer
In the early 1950s, Hoffmann-La Roche tasked Sternbach with creating a tranquilizer to rival the popular chlorpromazine. Sternbach, ever the innovator, chose to synthesize derivatives of a tricyclic skeleton different from chlorpromazine. His initial attempts, based on a structure he had worked with in Krakow, proved fruitless. Two years and two series of failed molecules later, Sternbach abandoned the project.
A Bit of Luck In A Dirty Lab
In 1957, while cleaning his laboratory, Sternbach stumbled upon two vials from his second series of molecules. On a whim, he sent one of the compounds, Ro 5-0690, for pharmacological testing. Days later, he received an enthusiastic call: the compound showed remarkable tranquilizing properties, outperforming meprobamate, chlorpromazine, and reserpine.
Sternbach was astonished. He re-examined the compound and realized it had a very different structure than he had imagined. This new compound belonged to a new chemical class: benzodiazepines. By 1960, it was marketed as chlordiazepoxide, or Librium, and just three years later, Sternbach's laboratory produced diazepam, or Valium.
Improving Chlordiazepoxide and the Creation of Valium
Sternbach's relentless pursuit of improvement led him to modify chlordiazepoxide, resulting in diazepam. Valium quickly replaced chlordiazepoxide and became one of the most prescribed drugs in the United States. Its success was followed by other benzodiazepines like oxazepam (Seresta) and lorazepam (Temesta).
The Dark Side of Serendipity
While the discovery of benzodiazepines was a boon for mental health, it also highlights the limitations of serendipity in drug discovery. Relying on chance can lead to missed opportunities and delayed breakthroughs. In contrast, the use of artificial intelligence (AI) in drug discovery promises a more systematic and efficient approach. AI can analyze vast amounts of data, predict molecular structures, and simulate pharmacological tests, potentially accelerating the development of new drugs.
Sternbach's Enduring Legacy
Despite the drawbacks of serendipity, Sternbach's contributions are undeniable. His work on benzodiazepines transformed Hoffmann-La Roche into a pharmaceutical giant and brought relief to millions suffering from anxiety and insomnia. Sternbach's legacy includes not just Valium and Librium, but also Klonopin, Mogadon, Dalmane, Quarzan, and Rohypnol.
What If AI Had Been Available?
Had Sternbach had access to AI, the history of benzodiazepines might have unfolded differently. AI could have predicted the structure of chlordiazepoxide and its tranquilizing properties, saving years of trial and error. The development of Valium and other benzodiazepines might have been expedited, and perhaps even more effective drugs could have been discovered sooner.
The discovery of benzodiazepines is a testament to the power of human ingenuity and a bit of luck. However, it also underscores the need for more systematic approaches in drug discovery. As we look to the future, AI holds the promise of revolutionizing the way we develop new medications, potentially leading to even greater breakthroughs in mental health treatment.
If you're interested by AI-driven drug discovery ??????
ITW Dr. Ivan De Weber, PhD - Cofounder-CEO at Cortex Discovery
Exciting news! ?? Join us for the next episode of our LinkedIn Live podcast featuring Dr. Ivan De Weber, PhD , co-founder and CEO of Cortex Discovery , a groundbreaking startup revolutionizing drug discovery through AI!
?? From Academia to AI-Powered Drug Discovery
Dr. de Weber's journey is nothing short of inspiring. We'll explore his transition from cellular biology and pharmaceutical bioinformatics to founding a company at the cutting edge of AI-driven drug discovery. Learn how his lifelong quest for longevity research led to the creation of Cortex Discovery.
?? Unveiling Cortex Discovery's Innovative Approach
Discover how Cortex Discovery is disrupting preclinical drug discovery across all therapeutic areas with their proprietary AI models. We'll delve into:
? Their foundation model for drug property predictions
? The vast database of 750 million data points powering their deep learning system
? Recent breakthroughs, including the first AI-discovered compound proven to extend lifespan in a whole organism
?? Business Insights and Future Outlook
Get an insider's perspective on:
? Cortex Discovery's unique business model and collaboration opportunities
? Challenges faced in the AI-driven drug discovery landscape
? The company's vision for the future of longevity research and pharmaceutical development
This episode is a must-watch for:
? Biotech and pharmaceutical executives
? Investors in the life sciences sector
? Academic researchers in pharmaceutical chemistry, longevity biology, and clinical medicine
? Anyone interested in the intersection of AI and drug discovery
Don't miss this opportunity to gain valuable insights into the future of AI-powered drug discovery and longevity research. Tune in to our LinkedIn Live podcast and be part of the conversation shaping the future of medicine!